US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

13.65

+0.68005.24%

Volume:387.91K

Turnover:5.18M

Market Cap:633.06M

PE:-2.70

High:13.93

Open:12.99

Low:12.32

Close:12.97

52wk High:40.43

52wk Low:9.10

Shares:46.38M

Float Shares:13.40M

Volume Ratio:0.65

T/O Rate:2.89%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.82

PE(LYR):-0.74

Loading ...

Overview Company News Filings

MapLight completes enrollment in Phase 2 ZEPHYR schizophrenia trial for ML-007C-MA

Maplight Therapeutics Inc - Topline Results From Both Phase 2 Trials Expected by Mid-August 2026

THOMSON REUTERS

MapLight Therapeutics Announces Board Refresh and New Nominees

MapLight Therapeutics announces annual shareholder meeting

A Look At MapLight Therapeutics (MPLT) Valuation After Its Sharp Recent Share Price Surge

Simply Wall St.

MapLight Therapeutics Leadership Quietly Unloads a Wave of Shares

Maplight director Robert C. Malenka sells 8,593 shares for $231,152

MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana

BUZZ-Needham initiates coverage of MapLight on schizophrenia drug potential

MapLight Therapeutics initiated with a Buy at Needham

Maplight Therapeutics Inc : Needham Initiates Coverage With Buy Rating; Target Price $37

THOMSON REUTERS

MapLight Therapeutics Initiated at Buy by TD Cowen

MapLight Therapeutics initiated with a Buy at TD Cowen

MapLight Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate

Benzinga Earnings

Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share

MT Newswires Live

MapLight Therapeutics FY2025 net loss more than doubled to $161 million; R&D expenses jump to $138 million

Maplight Therapeutics Inc - Q4 Net Loss $79.5 Mln, Q4 EPS $-2.47

THOMSON REUTERS

Press Release: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/MPLT/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":13.65,"timestamp":1788291405892,"preClose":12.97,"halted":0,"volume":387911,"delay":0,"changeRate":0.052428681572860424,"floatShares":13402700,"shares":46377800,"eps":-5.058,"marketStatus":"Trading","change":0.68,"latestTime":"09-01 15:36:51 EDT","open":12.99,"high":13.93,"low":12.32,"amount":5175261.8506040005,"amplitude":0.124133,"askPrice":13.7,"askSize":612,"bidPrice":13.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":12.97,"preHourTrading":{"tag":"盘前","latestPrice":12.64,"preClose":12.97,"latestTime":"09:06 EDT","volume":467,"amount":6081.369735,"timestamp":1788268008957,"change":-0.33,"changeRate":-0.025443,"amplitude":0.048574},"postHourTrading":{"tag":"盘后","latestPrice":12.97,"preClose":12.97,"latestTime":"19:30 EDT","volume":10891,"amount":141256.26,"timestamp":1788219003402,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.650028,"impliedVol":1.0477,"impliedVolPercentile":0.303},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":13402700,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":0.650028,"shares":46377800,"dividePrice":0,"high":13.93,"amplitude":0.124133,"preClose":12.97,"low":12.32,"week52Low":9.1,"pbRate":"1.82","week52High":40.43,"institutionHeld":0,"latestPrice":13.65,"committee":-0.719101,"eps":-5.058,"divideRate":0,"volume":387911,"delay":0,"ttmEps":-5.058,"open":12.99,"prevYearClose":17.565,"prevWeekClose":12.6,"prevMonthClose":12.97,"prevQuarterClose":35.84,"fiveDayClose":12.54,"twentyDayClose":12.94,"sixtyDayClose":28.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-08-31","current":-2.698695,"percent":0.9,"low":-9.047313,"twenty":-8.059278,"median":-7.418032,"eighty":-6.321753,"high":-2.251599,"avg":-6.888801,"sd":1.701235,"marketCap":700254059},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-28","current":-3.032366,"twenty":-8.06605,"median":-7.420317,"eighty":-6.349031,"marketCap":696919516},{"date":"2026-08-31","current":-3.046875,"twenty":-8.059278,"median":-7.418032,"eighty":-6.321753,"marketCap":700254059}],"updateTime":1788291411305},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2632619651","title":"MapLight completes enrollment in Phase 2 ZEPHYR schizophrenia trial for ML-007C-MA","url":"https://stock-news.laohu8.com/highlight/detail?id=2632619651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632619651?lang=en_us&edition=fundamental","pubTime":"2026-05-01 19:02","pubTimestamp":1777633348,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics completed enrollment in ZEPHYR Phase 2 trial of ML-007C-MA for schizophrenia, positioning program for near-term data readout.Topline results have not been presented; data from ZEPHYR expected by mid-August 2026.Separate IRIS Phase 2 trial of ML-004 in autism spectrum disorder finished final patient visit, moving study into analysis phase.IRIS topline results also scheduled for mid-August 2026, setting up a dual Phase 2 catalyst for MapLight.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL6xlplg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632619378","title":"Maplight Therapeutics Inc - Topline Results From Both Phase 2 Trials Expected by Mid-August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2632619378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632619378?lang=en_us&edition=fundamental","pubTime":"2026-05-01 19:00","pubTimestamp":1777633200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nTUA197CKJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631524381","title":"MapLight Therapeutics Announces Board Refresh and New Nominees","url":"https://stock-news.laohu8.com/highlight/detail?id=2631524381","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631524381?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:54","pubTimestamp":1777496096,"startTime":"0","endTime":"0","summary":"An update from MapLight Therapeutics, Inc. ( ($MPLT) ) is now available. On April 23, 2026, MapLight Therapeutics, Inc. announced that board member...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maplight-therapeutics-announces-board-refresh-and-new-nominees?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maplight-therapeutics-announces-board-refresh-and-new-nominees?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631525592","title":"MapLight Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631525592","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631525592?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493121,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics scheduled 2026 annual stockholder meeting for June 23, 2026, to be held virtually.Vote set on election of three Class I directors, including nominees Martin Babler, Troy Cox, George Pavlov.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5kPj1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628549750","title":"A Look At MapLight Therapeutics (MPLT) Valuation After Its Sharp Recent Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2628549750","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628549750?lang=en_us&edition=fundamental","pubTime":"2026-04-19 08:18","pubTimestamp":1776557927,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (MPLT) has drawn attention after a sharp share price move over the past month, with the stock closing at US$30.05 and a market value around US$1.24b, inviting closer scrutiny from biotech investors.\nSee our latest analysis for MapLight Therapeutics.\nThe recent 76.6% 30 day share price return, and 79.2% year to date share price return, point to strong short term momentum that contrasts with MapLight Therapeutics’ early stage fundamentals and lack of reported revenue so...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/a-look-at-maplight-therapeutics-mplt-valuation-after-its-sha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/a-look-at-maplight-therapeutics-mplt-valuation-after-its-sha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628735150","title":"MapLight Therapeutics Leadership Quietly Unloads a Wave of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2628735150","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628735150?lang=en_us&edition=fundamental","pubTime":"2026-04-18 10:02","pubTimestamp":1776477760,"startTime":"0","endTime":"0","summary":"New insider activity at MapLight Therapeutics, Inc. ( ($MPLT) ) has taken place on April 17, 2026. MapLight Therapeutics, Inc. insiders have recent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/maplight-therapeutics-leadership-quietly-unloads-a-wave-of-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/maplight-therapeutics-leadership-quietly-unloads-a-wave-of-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628479781","title":"Maplight director Robert C. Malenka sells 8,593 shares for $231,152","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479781","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628479781?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:06","pubTimestamp":1776456364,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics director Robert C. Malenka sold 8,593 voting common shares on April 15.Directly held stake fell to 316,466 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLc10tv7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight director Robert C. Malenka sells 8,593 shares for $231,152","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215929","title":"MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215929","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215929?lang=en_us&edition=fundamental","pubTime":"2026-04-09 02:29","pubTimestamp":1775672940,"startTime":"0","endTime":"0","summary":"Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/08/Alzheimers-test.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/08/Alzheimers-test.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51715454/maplights-psychosis-drug-could-deliver-billion-dollar-upside-says-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51715454/maplights-psychosis-drug-could-deliver-billion-dollar-upside-says-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0823421333.USD","LU1623119135.USD","LU1803068979.SGD","LU1861220207.SGD","LU1037948541.HKD","LU2404859741.USD","LU2420271590.USD","ADP","LU2462157665.USD","LU1814569148.SGD","IE00BHPRN162.USD","LU0965509101.SGD","LU0820561818.USD","LU2506952097.USD","LU0096362180.USD","BK4227","LU1261432733.SGD","LU2361045086.USD","LU2543165471.USD","LU0238689110.USD","LU0170899867.USD","MPLT","LU0889565833.HKD","LU0823434740.USD","LU0950375773.USD","LU2896262040.SGD","MA","LU0965509283.SGD","IE0004091025.USD","LU0545562505.USD","LU0868494708.USD","LU1145028129.USD","IE0004086264.USD","LU2168564222.USD","SGXZ41872573.SGD","LU1974910355.USD","LU0011850046.USD","LU1670628061.USD","LU1228905540.USD","IE00BFXG0V08.USD","LU0053666078.USD","LU1037948897.HKD","LU1868836757.USD","LU2361044865.SGD","LU2236285917.USD","LU2764263039.SGD","LU1989764664.SGD","LU2213496289.HKD","IE00BFSS7M15.SGD","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625894545","title":"BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana","url":"https://stock-news.laohu8.com/highlight/detail?id=2625894545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625894545?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:43","pubTimestamp":1775648638,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, HumanaWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL6N40R0UA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MOS","ANIP","FCX","BKNG","BTAI","HL","CCL","COIW","AMGN","OXY","IDXX","AAL","NEM","APO","SCCO","ZTS","NVAX","KKR","COIG","BAC","DVN","XOM","DAL","CVX","AEHR","MPLT","CF","CLSK","CDE","NCLH","OWL","FIAT","ELAN","MSTR","COIN","DE","HUM","VSAT","LUV","INSM","UAL","ABT","IBIO","BX","MSTP","GEMI","LEVI","EXPE","GATX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625594315","title":"BUZZ-Needham initiates coverage of MapLight on schizophrenia drug potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2625594315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625594315?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:11","pubTimestamp":1775646667,"startTime":"0","endTime":"0","summary":"BUZZ-Needham initiates coverage of MapLight on schizophrenia drug potential** Needham initiates coverage on Maplight Therapeutics MPLT.O with a \"buy\" rating and a PT of $37** Brokerage says MPLT's experimental lead drug ML-007C-MA is a safer and more convenient alternative to Bristol Myers Squibb's BMY.N drug, Cobenfy** Adds the drug is differentiated from Cobenfy in schizophrenia on tolerability and convenience with at least comparable efficacy, supporting $1.5 billion in sales by 2035** Says MPLT's drug could be even more differentiated from Cobenfy in Alzheimer's disease psychosis, including less frequent dosing, supporting sales of $2.4 billion by 2035** Mid-stage trial data for ML-007C-MA is expected in Q3 this year ** As of last close, MPLT shares up 37.4% YTD   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4N40R0X7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154778.USD","LU1868836757.USD","LU0321505868.SGD","LU1989771016.USD","LU1868837136.USD","LU1983299246.USD","IE00BFXG1179.USD","LU0225771236.USD","LU2360032135.SGD","BK4581","IE00BJT1NW94.SGD","LU0985481810.HKD","IE00B2B36J28.USD","LU1718418525.SGD","LU1883839398.USD","LU1074936037.SGD","LU1261432733.SGD","LU1670710588.SGD","IE0002141913.USD","LU2125154935.USD","BK4139","LU0114720955.EUR","LU1670711123.USD","LU2242652126.USD","LU0306806265.USD","LU0321505439.SGD","LU0456855351.SGD","LU1868837300.USD","LU0225284248.USD","IE00BSNM7G36.USD","LU0061475181.USD","BMY","LU1093756325.SGD","LU2242646821.SGD","LU1868836591.USD","BK4588","LU0868494617.USD","MPLT","BK4532","LU1868836914.USD","LU1430594728.SGD","LU0096364046.USD","LU1093756168.USD","BK4534","LU1670711040.USD","LU0306807586.USD","LU1291159041.SGD","IE00BJJMRZ35.SGD","LU1032466523.USD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625491791","title":"MapLight Therapeutics initiated with a Buy at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2625491791","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625491791?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:45","pubTimestamp":1775641512,"startTime":"0","endTime":"0","summary":"Needham initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $37 price target The firm believes the muscarinic class is likely ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625914143","title":"Maplight Therapeutics Inc : Needham Initiates Coverage With Buy Rating; Target Price $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2625914143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625914143?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:17","pubTimestamp":1775639843,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R0MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625956259","title":"MapLight Therapeutics Initiated at Buy by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2625956259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625956259?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:02","pubTimestamp":1775570520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2026 10:02 ET (14:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TD","BK4566","BK4139","BK4585","COWN","MPLT","BK4207","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625993969","title":"MapLight Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2625993969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625993969?lang=en_us&edition=fundamental","pubTime":"2026-04-07 17:41","pubTimestamp":1775554891,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and no price target The company is advancing candidates for the treat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","TD","BK4207","BK4566","MPLT","COWN","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622550866","title":"MapLight Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622550866","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622550866?lang=en_us&edition=fundamental","pubTime":"2026-03-26 22:11","pubTimestamp":1774534286,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMapLight Therapeutics Inc MPLT.OQ reported a quarterly adjusted loss of $2.47 per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E1G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851957","title":"MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851957","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851957?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:07","pubTimestamp":1774523234,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(2.47) per share which missed the analyst consensus estimate of $(0.96) by 156.49 percent. This is a 91.16 percent increase over losses of $(27.95) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51477253/maplight-therapeutics-q4-eps-2-47-misses-0-96-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985851","title":"Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622985851?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:05","pubTimestamp":1774523139,"startTime":"0","endTime":"0","summary":"Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622577851","title":"MapLight Therapeutics FY2025 net loss more than doubled to $161 million; R&D expenses jump to $138 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622577851","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622577851?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:03","pubTimestamp":1774523008,"startTime":"0","endTime":"0","summary":"MapLight published a fourth-quarter and full-year earnings press release, reporting FY net loss of USD 161.2 million and Q4 net loss of USD 79.5 million.FY R&D expense rose more than doubled to USD 138.3 million, driven mainly by clinical trial and CMC costs plus employee-related expenses including IPO-related stock-based compensation.Q4 G&A expense rose more than doubled to USD 18.8 million, primarily due to employee-related expenses including IPO-related stock-based compensation, as well as professional fees and other costs.Cash, cash equivalents and investments were USD 453.1 million as of Dec. 31, 2025, and MapLight said this is expected to fund operations through 2027.Clinical updates included Phase 2 ZEPHYR  expected to reach target enrollment of about 300 in April 2026 with topline data expected in Q3 2026, and Phase 2 IRIS  enrollment completed with topline data expected in Q3 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL4t8m79:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014021.USD","SG9999014005.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","MPLT","NDAQ","IE00BKPKM429.USD","BK4112","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BN0W2W23.USD","BK4139","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851902","title":"Maplight Therapeutics Inc - Q4 Net Loss $79.5 Mln, Q4 EPS $-2.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851902?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA7Z8R3G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985137","title":"Press Release: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622985137?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"-- Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach. target enrollment  in April 2026, with topline results expected in. -- Received FDA Fast Track designation for ML-007C-MA for Alzheimer's. disease psychosis; topline results from Phase 2 VISTA trial expected in. -- Expanded pipeline with a next-generation M1/M4 muscarinic agonist program,investments, which is expected to fund operations through 2027. \"With a focused strategy, robust operational execution and a strong balance sheet, MapLight is well positioned to deliver on multiple key development milestones in 2026,\" said Chris Kroeger, co-Founder and Chief Executive Officer of the Company. \"While continuing to prioritize high-quality trial execution, we have maintained a robust enrollment pace in the ZEPHYR study and expect to reach target enrollment in April 2026. This is shaping up to be an exciting year for MapLight as we look forward to reporting topline results from our Phase 2 ZEPHYR trial and ML-004 Pha","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2506952097.USD","SG9999002232.USD","LU2404859741.USD","BK4585","LU1363072403.SGD","LU2063271972.USD","LU0109391861.USD","BK4613","BK4227","GB00BDT5M118.USD","IE0004086264.USD","LU2506951875.HKD","LU1814569148.SGD","SGXZ81514606.USD","LU0096362180.USD","LU0957791311.USD","IE0004091025.USD","LU0965509101.SGD","LU0053666078.USD","LU1084165304.USD","LU0094547139.USD","ADP","LU2552382132.HKD","LU0708995401.HKD","LU0889565833.HKD","LU2054465674.USD","BK4528","BK4566","LU2506951958.HKD","LU0823434583.USD","BK4527","LU2023250330.USD","LU2092627202.USD","LU0942090050.USD","LU2456880835.USD","MPLT","IE0004445015.USD","MA","LU1221951129.SGD","LU2317271919.USD","LU1551013342.USD","IE00B1XK9C88.USD","BK4534","LU1037948897.HKD","BK4130","LU0345769128.USD","LU2896262040.SGD","LU0210536198.USD","BK4588","LU1153585028.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":123,"code":"91000000","status":"200"}]}}